Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stanley R Riddell

Showing results (161-170 of 177) with videos related to

Pageof 18
Sort By:
Cancer Discovery|March 23, 2018
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman PrimatesAgne Taraseviciute, Victor Tkachev, Rafael Ponce, et al.
Science Immunology|April 19, 2024
TIM-3<sup>+</sup> CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignanciesSimone A Minnie, Olivia G Waltner, Ping Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2024
Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial MalignanciesCarla A Jaeger-Ruckstuhl, Jennifer M Specht, Jenna M Voutsinas, et al.
Molecular Cancer Therapeutics|April 11, 2022
B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma ModelShihong Zhang, R Graeme Black, Karan Kohli, et al.
Blood|April 28, 2016
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHLXiuli Wang, Leslie L Popplewell, Jamie R Wagner, et al.
Blood|April 8, 2025
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-upSherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, et al.
Blood Advances|October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.
Cancer|May 3, 2017
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomasSeth M Pollack, Qianchuan He, Jennifer H Yearley, et al.
Blood|February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Nature|January 11, 2019
De novo design of potent and selective mimics of IL-2 and IL-15Daniel-Adriano Silva, Shawn Yu, Umut Y Ulge, et al.
Pageof 18

Showing results (161-170 of 177) with videos related to

Sort By:
Pageof 18
Cancer Discovery|March 23, 2018
Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman PrimatesAgne Taraseviciute, Victor Tkachev, Rafael Ponce, et al.
Science Immunology|April 19, 2024
TIM-3<sup>+</sup> CD8 T cells with a terminally exhausted phenotype retain functional capacity in hematological malignanciesSimone A Minnie, Olivia G Waltner, Ping Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 28, 2024
Phase I Study of ROR1-Specific CAR-T Cells in Advanced Hematopoietic and Epithelial MalignanciesCarla A Jaeger-Ruckstuhl, Jennifer M Specht, Jenna M Voutsinas, et al.
Molecular Cancer Therapeutics|April 11, 2022
B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma ModelShihong Zhang, R Graeme Black, Karan Kohli, et al.
Blood|April 28, 2016
Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHLXiuli Wang, Leslie L Popplewell, Jamie R Wagner, et al.
Blood|April 8, 2025
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-upSherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, et al.
Blood Advances|October 30, 2023
Timing of anti-PD-L1 antibody initiation affects efficacy/toxicity of CD19 CAR T-cell therapy for large B-cell lymphomaAlexandre V Hirayama, Erik L Kimble, Jocelyn H Wright, et al.
Cancer|May 3, 2017
T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomasSeth M Pollack, Qianchuan He, Jennifer H Yearley, et al.
Blood|February 8, 2019
Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapyKevin A Hay, Jordan Gauthier, Alexandre V Hirayama, et al.
Nature|January 11, 2019
De novo design of potent and selective mimics of IL-2 and IL-15Daniel-Adriano Silva, Shawn Yu, Umut Y Ulge, et al.
Pageof 18